Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS’s (“GA” or the “Company”) warrants of series TO 1, issued in connection with the Company’s IPO of units in September/October 2021, ended. No warrants of series TO 1 have been exercised. The reason for this is deemed to be that the subscription price for the exercise of warrants of series TO 1 has exceeded the current share price during the entire exercise period.
During the period November 2 until November 16, 2022, holders of warrants of series TO 1 were, for each warrant, entitled to subscribe for one (1) new share in GA, at a subscription price set to NOK 9.30 per share. No warrants have been exercised, and therefore, the share capital and the number of shares in the Company remain unchanged.
For more information about warrants of series TO 1, please contact:
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com
Website: www.genetic-analysis.com
For more information about GA, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com
Please read the full press release in English here:
Please also see the full Swedish press release: